Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this module, Christopher R. Flowers, MD, MS, first reviews the biologic rationale and clinical role of Bruton tyrosine kinase (BTK) inhibitors in treating hematologic malignancies, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). Then, Dr. Flowers discusses practical strategies for multidisciplinary management of BTK inhibitor–related adverse events (AEs) and identifies particular patient populations who may be at higher risk.
The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.
Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.
Before continuing with this educational activity, please take a moment to answer the following questions.